Can I Take Resveratrol with Praluent (Alirocumab)? A Women's Health Guide

What Is the Interaction Risk Between Resveratrol and Praluent?

The short answer is that no pharmacokinetic drug interaction has been identified between resveratrol and alirocumab. Alirocumab is a fully human monoclonal IgG1 antibody. It does not travel through the CYP450 enzyme system the way small-molecule drugs do. It is broken down by proteolytic degradation into amino acids and peptides, a pathway resveratrol does not meaningfully touch.

Resveratrol (trans-3,4,5-trihydroxystilbene), the polyphenol found in grape skin, red wine, and Japanese knotweed, does inhibit CYP3A4 and CYP2C9 in vitro. Those enzyme interactions matter enormously for statins, warfarin, and other small-molecule drugs. They do not apply to a monoclonal antibody like alirocumab.

Three areas still warrant a conversation with your prescriber: resveratrol's modest lipid effects, its estrogenic signaling, and the general principle that adding any bioactive supplement to a cardiovascular drug regimen deserves documentation and monitoring.

Why Alirocumab's Mechanism Matters Here

Alirocumab inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab allows more LDL receptors to survive on the cell surface, pulling more LDL cholesterol out of circulation. In the ODYSSEY LONG TERM trial (n=2,341), alirocumab 150 mg every two weeks reduced LDL-C by a mean of 61% from baseline at 24 weeks. Because the drug acts on a cell-surface receptor pathway rather than through hepatic CYP metabolism, supplement-driven CYP inhibition is irrelevant to its clearance.

Where Resveratrol's CYP Activity Actually Matters

If you are on a statin alongside alirocumab, the picture changes. Simvastatin and lovastatin are heavily CYP3A4-dependent. High-dose resveratrol (typically studied at 500 mg to 2,000 mg per day in trials, far above the 150-500 mg range in most commercial supplements) may theoretically raise statin exposure. The clinical evidence for this in women is thin. Most CYP inhibition data comes from in vitro or small mixed-sex studies, and women have been historically under-represented in pharmacokinetic trials. Until sex-stratified PK data exist, caution with high-dose resveratrol and CYP3A4-sensitive statins is reasonable, even if it does not affect alirocumab itself.

Does Resveratrol Affect LDL or Cardiovascular Risk in Women?

Resveratrol's direct effect on LDL is modest and inconsistent across trials. A 2017 meta-analysis of 21 randomized controlled trials found that resveratrol supplementation did not significantly reduce LDL-C overall, though triglycerides fell modestly in diabetic subgroups. Contrast that with alirocumab's 60-plus percent LDL reduction, and the pharmacodynamic contribution of resveratrol becomes minor at best.

What This Means If You Are Already on Praluent

Taking resveratrol alongside alirocumab is unlikely to meaningfully blunt or amplify its LDL-lowering effect. The mechanisms are additive at most, and the net pharmacodynamic interaction is not clinically significant based on current data. Your LDL panel should be re-checked 4 to 12 weeks after any alirocumab dose adjustment, per standard practice, regardless of whether you add a supplement.

Resveratrol and Inflammation

Resveratrol activates SIRT1 and inhibits NF-kB, pathways linked to reduced vascular inflammation. Some researchers have proposed this could complement PCSK9 inhibition's plaque-stabilizing effects. The hypothesis is biologically plausible, but no prospective trial has tested resveratrol as an adjunct to a PCSK9 inhibitor in a female-majority cohort. This is an evidence gap. Do not assume benefit where none has been demonstrated in women.

Resveratrol as a Phytoestrogen: Why This Matters for Women on Praluent

This section matters more than the CYP discussion for most women reading this. Resveratrol binds to both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with a preference for ERβ. Its estrogenic potency is far weaker than estradiol, but it is not zero. A 2010 study in postmenopausal women found that resveratrol at 75 mg per day activated ERβ-dependent gene expression in peripheral blood mononuclear cells.

Postmenopausal Women and ASCVD Risk

Women are more likely to be prescribed alirocumab after menopause, because cardiovascular risk rises sharply at that transition. PCSK9 levels increase significantly after menopause, contributing to higher LDL-C in postmenopausal women. If you are postmenopausal and on alirocumab, resveratrol's weak estrogenic signaling is generally considered low-risk in the absence of hormone-sensitive cancer, but it is worth disclosing to your cardiologist or women's health provider.

Women with Hormone-Sensitive Conditions

If you have a history of ER-positive breast cancer, estrogen-receptor-positive uterine cancer, or are being treated with an aromatase inhibitor, resveratrol's estrogenic activity is a real clinical concern. The American College of Obstetricians and Gynecologists advises caution with phytoestrogens in women with hormone-sensitive malignancies. Taking resveratrol in this setting requires explicit discussion with your oncologist, separate from any conversation about alirocumab.

Perimenopausal Women

In perimenopause, estrogen levels fluctuate erratically. Resveratrol's ERβ activity could theoretically modulate those fluctuations, but no controlled trial has examined this in perimenopausal women specifically. The evidence gap is large. If you are perimenopausal and are also managing rising LDL-C, which does climb during the menopause transition, prioritize the conversation about statin therapy or alirocumab eligibility with your provider before adding resveratrol.

Women with PCOS

Polycystic ovary syndrome is associated with dyslipidemia, insulin resistance, and elevated cardiovascular risk even in younger reproductive-age women. A 2016 randomized controlled trial (n=30) found that resveratrol 1,500 mg per day for three months reduced testosterone and DHEA-S and improved insulin sensitivity in women with PCOS. Whether those findings justify resveratrol use alongside lipid-lowering therapy in younger women with PCOS and familial hypercholesterolemia is unstudied. Do not combine them without a clinician's guidance.

Pregnancy, Lactation, and Contraception: What Every Woman on Praluent Must Know

Alirocumab is contraindicated in pregnancy. This is not a category classification footnote. It is a firm clinical instruction.

Alirocumab in Pregnancy

The FDA label for alirocumab states that animal reproduction studies showed adverse fetal effects at doses producing exposure greater than or equal to approximately 1 times the human exposure at 150 mg every 2 weeks. Human data are absent because pregnant women were excluded from all ODYSSEY trials. Alirocumab is an IgG1 antibody and crosses the placenta via FcRn-mediated transport, particularly in the second and third trimesters, meaning fetal exposure is expected. There is no safe threshold established. If you are of reproductive age and prescribed alirocumab, reliable contraception is required for the duration of treatment.

The half-life of alirocumab is approximately 17 to 20 days. If you plan a pregnancy, discuss with your cardiologist how far in advance to discontinue and what bridge therapy (if any) is appropriate for your cardiovascular risk level.

Alirocumab During Lactation

No human data exist on alirocumab transfer into breast milk. Given that IgG antibodies are present in breast milk, some transfer is biologically plausible. The prescribing information advises that the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for alirocumab and any potential adverse effects on the infant. This is a decision to make with your prescriber and pediatrician, weighing your cardiovascular risk against the uncertainty.

Resveratrol in Pregnancy and Lactation

Resveratrol's safety in pregnancy is unknown. In animal models, high-dose resveratrol has shown mixed effects on fetal development, including disruption of pancreatic beta-cell development in primate models at supplemental doses. A 2011 study in macaques found that maternal resveratrol supplementation altered fetal pancreatic development and increased fetal fat mass. Extrapolation from primates to humans is imperfect, but the signal is concerning enough that resveratrol supplements should be avoided during pregnancy and breastfeeding. This applies regardless of whether you are also on alirocumab.

Who This Combination Is and Is Not Right For

Women Who May Reasonably Take Both

• Postmenopausal women on alirocumab for familial hypercholesterolemia or established ASCVD who are not on CYP3A4-sensitive statins and have no hormone-sensitive cancer history
• Women taking low-to-moderate resveratrol doses (150 to 500 mg per day) who disclose the supplement to their prescribing cardiologist or internist
• Women whose lipid panel is being actively monitored every 3 to 6 months

Women Who Should Avoid Resveratrol While on Alirocumab

• Any woman who is pregnant, trying to conceive, or breastfeeding (resveratrol should be stopped; alirocumab is also contraindicated in pregnancy)
• Women with a history of ER-positive breast cancer or uterine cancer, or those on aromatase inhibitors
• Women on CYP3A4-sensitive statins (simvastatin, lovastatin) alongside alirocumab, where high-dose resveratrol could theoretically raise statin exposure
• Women taking resveratrol at doses above 1,000 mg per day without medical supervision

Monitoring and Practical Steps If You Are Already Taking Both

Your alirocumab efficacy is not threatened by resveratrol at typical supplement doses. The monitoring plan for alirocumab does not change. Here is what a practical protocol looks like:

1. Tell your prescriber. Document the resveratrol dose, brand, and frequency in your medication list. Supplements are often omitted from records, and omission creates risk when other medications are added later.
2. Check your LDL-C at 4 to 12 weeks after starting or adjusting alirocumab, per ODYSSEY trial monitoring intervals. If LDL is not at goal, the issue is almost certainly not resveratrol.
3. If you are perimenopausal or postmenopausal, ask your women's health provider whether resveratrol's ERβ activity is appropriate given your hormone-sensitive history.
4. If you add a statin to your regimen, revisit the resveratrol dose. Move to a CYP3A4-insensitive statin (rosuvastatin, pravastatin, fluvastatin) if you want to keep resveratrol without CYP concern.
5. Do not exceed 500 mg per day of resveratrol without specific clinical justification. The PCOS trial cited above used 1,500 mg under study conditions with close monitoring. Commercial "megadose" resveratrol products are not equivalent to a supervised trial.

Sex-Specific Pharmacokinetics: What We Know and Don't Know

Women metabolize many drugs differently than men. Body composition, hormonal status, and sex-based differences in CYP enzyme expression all play a role. Women show higher CYP3A4 activity on average than men, which affects drugs cleared by that enzyme. Because alirocumab bypasses CYP metabolism entirely, this sex difference does not alter its kinetics. Its clearance is driven by PCSK9 target-mediated drug disposition and non-specific IgG clearance pathways, both of which are not meaningfully different between sexes based on population PK data from the ODYSSEY program.

Resveratrol's own pharmacokinetics show high inter-individual variability. Oral bioavailability is low, roughly 1% for free resveratrol after first-pass metabolism, and most circulating forms are sulfate and glucuronide conjugates. Sex-stratified resveratrol PK data in humans are limited, which is an evidence gap that matters. Whether hormonal status in premenopausal versus postmenopausal women alters resveratrol's bioavailability or estrogenic potency has not been rigorously studied. This uncertainty should factor into your decision.

What the Guidelines Say

No major cardiovascular guideline (ACC/AHA, ESC) or women's health guideline (ACOG, The Menopause Society) has issued a specific recommendation on resveratrol supplementation alongside PCSK9 inhibitors. That silence is not permission. It reflects an absence of trial data, not a clinical endorsement.

The 2022 ACC/AHA Guideline on the Management of Patients with Chronic Coronary Disease recommends PCSK9 inhibitors as second-line or adjunct therapy after maximally tolerated statins in high-risk patients, with no guidance on concurrent supplements. The Menopause Society's 2023 position statement on cardiovascular disease notes that postmenopausal women have an accelerated ASCVD trajectory and benefit from aggressive LDL management, but does not address phytoestrogen supplementation in this context.

ACOG Committee Opinion 754 notes that evidence for most dietary supplements in women's cardiovascular health remains insufficient to support routine recommendation.